Atala, A., Bauer, S. B., Soker, S., Yoo, J. J., & Retik, A. B. (2006). Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet, 367(9518), 1241–1246.
Bretzner, F., Gilbert, F., Baylis, F., & Brownstone, R. M. (2011). Target populations for first-in-human embryonic stem cell research in spinal cord injury. Cell Stem Cell, 8(5), 468–475.
Clinicaltrials.gov. (2015). NCT02559050 Nasal reconstruction using a customized 3D-printed nasal stent for congenital arhinia. Clinicaltrials.gov A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT02559050. Accessed August 12 2016.
Cohen, I. G. (2013). Transplant tourism: The ethics and regulation of international markets for organs. The Journal of Law, Medicine & Ethics, 41(1), 269–285.
Cornwall, J. (2016). The ethics of 3D printing copies of bodies donated for medical education and research. Australasian Medical Journal, 9(1), 8–11.
Davies, C. T., Baird, L. M., Jacobson, M. D., Tabibkhoei, F., Beck, J. M., Daubert, G. L., et al. (2015). 3D printing of medical devices: When a novel technology meets traditional legal principles. White paper. Life Sciences Industry Group. http://www.reedsmith.com/files/Publication/130448b9-7565-4295-a697-5c5d7c6eb516/Presentation/PublicationAttachment/9ba9b53c-2009-488d-ba91-5cc5a19a38f7/3d-printing-white-paper_79444049.pdf. Accessed August 1 2016.
de Vries, R. B. M., Oerlemans, A., Trommelmans, L., Dierickx, K., & Gordijn, B. (2008). Ethical aspects of tissue engineering: A review. Tissue Engineering Part B: Reviews, 14(4), 367–375.
de Wert, G., & Mummery, C. (2003). Human embryonic stem cells: Research, ethics and policy. Human Reproduction, 18(4), 672–682.
Dodds, S. (2015). 3D printing raises ethical issues in medicine. ABC Science. http://www.abc.net.au/science/articles/2015/02/11/4161675.htm. Accessed March 1 2016.
Dukehealth.org. (2015). 3D printed bone implant saves woman’s leg. DukeHealth. http://www.dukehealth.org/blog/3-d-printed-bone-implant-saves-womans-leg. Accessed March 1 2016.
Enoch, S., Shaaban, H., & Dunn, K. W. (2005). Informed consent should be obtained from patients to use products (skin substitutes) and dressings containing biological material. Journal of Medical Ethics, 31(1), 2–6.
FDA.gov. (2014a). Food and Drug Administration (FDA) public additive manufacturing of medical devices: An interactive discussion on medical considerations of 3D printing. U.S. Department of Health and Human Services Food and Drug Administration. http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm397324.htm. Accessed March 1 2016.
FDA.gov. (2014b). Food and Drug Administration (FDA) public workshop additive manufacturing of medical devices: An interactive discussion on medical considerations of 3D printing. U.S. Department of Health and Human Services Food and Drug Administration. http://www.fda.gov/downloads/MedicalDevices/NewsEvents/WorkshopsConferences/UCM425399.pdf. Accessed March 1 2016.
FDA.gov. (2016). Technical considerations for additive manufactured devices. Draft guidance for industry and Food and Drug Administration staff. U.S. Department of Health and Human Services Food and Drug Administration. http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm499809.pdf. Accessed August 1 2016.
Fedorovich, N. E., Oudshoorn, M. H., van Geemen, D., Hennink, W. E., Alblas, J., & Dhert, W. J. (2009). The effect of photopolymerization on stem cells embedded in hydrogels. Biomaterials, 30(3), 344–353.
Gartner.com. (2014). Gartner says uses of 3D printing will ignite major debate on ethics and regulation. Gartner. http://www.gartner.com/newsroom/id/2658315. Accessed March 1 2016.
Gilbert, F. (2012). The burden of normality: From ‘chronically ill’ to ‘symptom free’. New ethical challenges for deep brain stimulation postoperative treatment. Journal of Medical Ethics, 38(7), 408–412.
Gilbert, F. (2013a). Deep brain stimulation for treatment resistant depression: Postoperative feelings of self-estrangement. Suicide Attempt and Impulsive-Aggressive Behaviours, Neuroethics, 6(3), 473–481. doi:10.1007/s12152-013-9178-8.
Gilbert, F. (2013b). Deep brain stimulation and postoperative suicidability among treatment resistant depression patients: Should eligibility protocols exclude patients with history of suicide attempts and anger/impulsivity? American Journal of Bioethics: Neuroscience, 4(1), 28–35. doi:10.1080/21507740.2012.740143.
Gilbert, F. (2014). Self-estrangement & deep brain stimulation: Ethical issues related to forced explantation. Neuroethics, 8(2), 107–114. doi:10.1007/s12152-014-9224-1.
Gilbert, F. (2015). A threat to autonomy? The intrusion of predictive brain devices. American Journal of Bioethics: Neuroscience, 6(4), 4–11. doi:10.1080/21507740.2015.1076087.
Gilbert, F., & Dodds, S. (2014). Is there a moral obligation to develop brain implants involving nanobionics technologies? Ethical issues for clinical trials. Nanoethics, 8, 49–56. doi:10.1007/s11569-013-0177-3.
Gilbert, F., & Cook, M. (2015). Are predictive brain implants an indispensable feature of autonomy? Bioethica Forum, 8(4), 121–127.
Gilbert, F., Harris, A., Dodds, S., & Kapsa, R. (2015). Is a ‘last chance’ treatment possible after an irreversible brain intervention? AJOB Neuroscience, 6(2), W1–W2. doi:10.1080/21507740.2015.1037469.
Gilbert, F., Harris, A., & Kapsa, R. (2012). Efficacy testing as a primary purpose of Phase 1 clinical trials: Is it applicable to first-in-human bionics and optogenetics trials? American Journal of Bioethics: Neuroscience, 3(2), 20–22.
Gilbert, F., Harris, A., & Kapsa, R. (2014). Controlling brain cells with light: Ethical considerations for optogenetics trials. American Journal of Bioethics: Neuroscience, 5(3), 3–11.
GPO.gov. (2014). Additive manufacturing of medical devices: An interactive discussion on the technical considerations of 3-D printing. http://www.gpo.gov/fdsys/pkg/FR-2014-05-19/html/2014-11513.htm. Accessed March 1 2016.
Gutierrez-Aranda, I. (2010). Human induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells regardless the site of injection. Stem Cells, 28(9), 1568–1570.
Harris, W. H. (2009). The first 50 years of total hip arthroplasty: Lessons learned. Clinical Orthopaedics and Related Research, 467(1), 28–31.
Hess, P. (2012). Intracranial stem cell-based transplantation: Reconsidering the ethics of phase 1 clinical trials in light of irreversible interventions in the brain. American Journal of Bioethics: Neuroscience, 3(2), 3–13.
Hilleman, M. R. (1998). Discovery of simian virus 40 (SV40) and its relationship to poliomyelitis virus vaccines. Developments in Biological Standardization, 94, 183–190.
Hollister, S. J., Flanagan, C. L., Zopf, D. A., Morrison, R. J., Nasser, H., Patel, J. J., et al. (2015). Design control for clinical translation of 3D printed modular scaffolds. Annals of Biomedical Engineering, 43(3), 774–786.
Hyun, I. (2010). The bioethics of stem cell research and therapy. The Journal of Clinical Investigations, 120, 71–75.
Ipscell.com. (2015). Landmark IPSC clinical study on hold due to genomic issue. The Niche Knoepfler lab stem cell blog. http://www.ipscell.com/2015/07/firstipscstop/. Accessed March 1 2016.
Jabr, F. (2012). In the flesh: The embedded dangers of untested stem cell cosmetics. Scientific American. http://www.scientificamerican.com/article/stem-cell-cosmetics/. Accessed March 21 2016.
Kang, H. W., Lee, S. J., Ko, I. K., Kengla, C., Yoo, J. J., & Atala, A. (2016). A 3D bioprinting system to produce human-scale tissue constructs with structural integrity. Nature Biotechnology, 34(3), 312–319.
Kimbrel, E. A., & Lanza, R. (2015). Current status of pluripotent stem cells: Moving the first therapies to the clinic. Nature Reviews Drug Discovery, 14(10), 681–692.
Kimmelman, J. (2012). A theoretical framework for early human studies: Uncertainty, intervention ensembles, and boundaries. Trials, 13, 173.
Lane, E. (2013). Science and society: Experts warn against 3D printing. Science, 342(6157), 439.
Lindvall, O., Kokaia, Z., & Martinez-Serrano, A. (2004). Stem cell therapy for human neurodegenerative disorders—How to make it work. Nature Medicine, 10(Suppl), S42–S50.
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Jr., Mingozzi, F., Bennicelli, J., et al. (2008). Safety and efficacy of gene transfer for Leber’s congenital amaurosis. New England Journal of Medicine, 358(21), 2240–2248.
Marchioli, G., van Gurp, L., van Krieken, P. P., Stamatialis, D., Engelse, M., & van Blitterswijk, C. A. (2015). Fabrication of three-dimensional bioplotted hydrogel scaffolds for islets of Langerhans transplantation. Biofabrication, 7(2), 025009. doi:10.1088/1758-5090/7/2/025009.
Martina, M., & Hutmacher, D. W. (2007). Biodegradable polymers applied in tissue engineering research: A review. Polymer International, 56(2), 145–157.
Mattox, J. M. (2013). Additive manufacturing and its implications for military ethics. Journal of Military Ethics, 12, 225–234.
MFDS. (2015). Guidance for approval and review of custom devices manufactured using 3D printers. Ministry of Food and Drug Safety. http://www.mfds.go.kr/eng/eng/download.do;jsessionid=aku16DUHEgsPrxyxLwUzqcjMDFm5HA1dAaajbIwUqZWcTsiTQh1mX7XSSqgC2F07?boardCode=17841&boardSeq=70109&fileSeq=1. Accessed August 21 2016.
Mill, J. S. (1998). In R. Crisp (Ed.), Utilitarianism. London: Oxford University Press.
Morrison, R. J., Hollister, S. J., Niedner, M. F., Mahani, M. G., Park, A. H., Mehta, D. K., et al. (2015a). Mitigation of tracheobronchomalacia with 3D-printed personalized medical devices in pediatric patients. Science Translational Medicine, 7, 285ra64, doi:10.1126/scitranslmed.3010825.
Morrison, R. J., Kashlan, K. N., Flanangan, C. L., Wright, J. K., Green, G. E., Hollister, S. J., et al. (2015b). Regulatory considerations in the design and manufacturing of implantable 3D-printed medical devices. Clinical and Translational Science, 8(5), 594–600.
Munsie, M., & Hyun, I. (2014). A question of ethics: Selling autologous stem cell therapies flaunts professional standards. Stem Cell Research, 13(3), 647–653.
Murphy, S. V., & Atala, A. (2014). 3D bioprinting of tissues and organs. Nature Biotechnology, 32(8), 773–785.
Nair, K., Gandhi, M., Khalil, S., Yan, K. C., Marcolongo, M., Barbee, K., et al. (2009). Characterization of cell viability during bioprinting processes. Biotechnology Journal, 4(8), 1168–1177.
Nakano-Okuno, M., Rashmi Borah, B., & Nakano, I. (2014). Ethics of iPSC-based clinical research for age-related macular degeneration: Patient-centered risk-benefit analysis. Stem Cell Reviews, 10(6), 743–752.
Neely, E. L. (2015). The risks of revolution: Ethical dilemmas in 3D printing from a US perspective. Science and Engineering Ethics. doi:10.1007/s11948-015-9707-4.
O’Connell, C. D., Di Bella, C., Thompson, F., Augustine, C., Beirne, S., Cornock, R., et al. (2016). Development of the Biopen: A handheld device for surgical printing of adipose stem cells at a chondral wound site. Biofabrication, 8(1), 015019. doi:10.1088/1758-5090/8/1/015019.
Petersen, A., & Seear, K. (2011). Technologies of hope: Techniques of the online advertising of stem cell treatments. New Genetics and Society, 30(4), 329–346.
Pule, M., Finney, H., & Lawson, A. (2003). Artificial T-cell receptors. Cytotherapy, 5(3), 211–226.
Ratner, B. D., & Bryant, S. J. (2004). Biomaterials: Where we have been and where we are going. Annual Review of Biomedical Engineering, 6, 41–75.
Schothorst, M. V., Weeda, J., Schiffers, K., Oortwijn, W., Hoekman, J., Coppens, D., et al. (2016). Study on the regulation of advanced therapies in selected jurisdictions. European Commission.http://ec.europa.eu/health/human-use/docs/20147306_rfs_chafea_2014_health_24_060516.pdf. Accessed August 1 2016.
Segers, V. F. M., & Lee, R. T. (2008). Stem-cell therapy for cardiac disease. Nature, 451, 937–942.
Skerritt, J. (2015). Impact of innovative therapies on the regulation of therapeutic goods—Presentation at the ARCS AGM Melbourne, 26 November, 2015. Slideshow presentation. Australian Government Department of Health and Ageing Therapeutic Goods Administration. http://www.tga.gov.au/presentation-impact-innovative-therapies-regulation-therapeutic-goods. Accessed August 12 2016.
Tasoglu, S., & Demirci, U. (2013). Bioprinting for stem cell research. Trends in Biotechnology, 31(1), 10–19.
TGA. (2011). Australian regulatory guidelines for medical devices (ARGMD). Australian Government Department of Health and Ageing Therapeutic Goods Administration. http://www.tga.gov.au/sites/default/files/devices-argmd-01.pdf. Accessed August 1 2016.
TGA. (2013). Excluded Goods Order No. 1 of 2011: Guideline for Items 4(o), 4(p), 4(q) and 4(r). Australian Government Department of Health Therapeutic Goods Administration. http://www.tga.gov.au/excluded-goods-order-no-1-2011-guideline-items-4o-4p-4q-and-4r. Accessed August 12 2016.
TGA. (2014). Australian regulatory guidelines for biologicals (ARGB). Australian Government Department of Health Therapeutic Goods Administration. http://www.tga.gov.au/publication/australian-regulatory-guidelines-biologicals-argb. Accessed August 12 2016.
Thirabanjasak, D., Tantiwongse, K., & Thorner, P. S. (2010). Angiomyeloproliferative lesions following autologous stem cell therapy. Journal of the American Society of Nephrology, 21(7), 1218–1222.
Tran, J. L. (2015). To bioprint or not to bioprint. North Carolina Journal of Law and Technology, 17(1), 123–178.
Trommelmans, L., Selling, J., & Dierickx, K. (2007). Ethical issues in tissue engineering. Leuven: European Ethical-Legal Papers No. 7.
Vacanti, J. P., & Langer, R. (1999). Tissue engineering: The design and fabrication of living replacement devices for surgical reconstruction and transplantation. Lancet, 354(Suppl 1), S32–S34.
Varkey, M., & Atala, A. (2015). Organ bioprinting: A closer look at ethics and policies. Wake Forest Journal of Law & Policy, 5(2), 275–298.
Wadman, M. (2013). High court ensures continued US funding of human embryonic-stem-cell research. Nature. http://www.nature.com/news/high-court-ensures-continued-us-funding-of-human-embryonic-stem-cell-research-1.12171. Accessed October 16 2015.
Wallace, G., Cornock, R., O’Connell, C., Beirne, S., Gilbert, F., & Dodds, S. (2014). 3D bioprinting: Printing parts for bodies. Australia: ARC Centre of Excellence for Electromaterials Science.
Wolf, M. J., & Fresco, N. (2016), My liver is broken, can you print me a new one? In V. C. Müller (Ed.), Computing and philosophy: Selected papers from IACAP 2014, Synthese Library, 375 (pp. 259–269). Berlin: Springer.
Xu, F., Sridharan, B., Wang, S., Gurkan, U. A., Syverud, B., & Demirci, U. (2011). Embryonic stem cell bioprinting for uniform and controlled size embryoid body formation. Biomicrofluidics, 5(2), 22207. doi:10.1063/1.3580752.
Zopf, D. A., Hollister, S. J., Nelson, M. E., Ohye, R. G., & Green, G. E. (2013). Bioresorbable airway splint created with a three-dimensional printer. New England Journal of Medicine, 368, 2043–2045.